Detailed Mechanism Funding and Narrative

Years of mechanism: 2015 2016 2017 2018

Details for Mechanism ID: 17967
Country/Region: Eswatini
Year: 2017
Main Partner: The Luke Commission
Main Partner Program: NA
Organizational Type: FBO
Funding Agency: USAID
Total Funding: $2,188,588 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $282,583
Care: TB/HIV (HVTB) $23,098
Care: Pediatric Care and Support (PDCS) $5,354
Laboratory Infrastructure (HLAB) $6,946
Strategic Information (HVSI) $21,350
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $472,778
Testing: HIV Testing and Counseling (HVCT) $170,822
Sexual Prevention: Other Sexual Prevention (HVOP) $754,130
Treatment: Adult Treatment (HTXS) $444,388
Treatment: Pediatric Treatment (PDTX) $7,139
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2018 7,129
HTS_TST Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Negative 2018 194
HTS_TST Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Negative 2018 98
HTS_TST Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Negative 2018 4,756
HTS_TST Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Negative 2018 1,772
HTS_TST Sum of Test Result disaggregates 2018 309
HTS_TST_POS By Test Result: Positive 2018 309
HTS_TST_POS Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Female, Positive 2018 10
HTS_TST_POS Service Delivery Point by Agg Age(Community) Mobile Testing: <15, Male, Positive 2018 5
HTS_TST_POS Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Female, Positive 2018 220
HTS_TST_POS Service Delivery Point by Agg Age(Community) Mobile Testing: 15+, Male, Positive 2018 74
PP_PREV Age/sex: 10-14 Female 2018 200
PP_PREV Age/sex: 10-14 Male 2018 200
PP_PREV Age/sex: 15-19 Female 2018 5,200
PP_PREV Age/sex: 15-19 Male 2018 1,000
PP_PREV Age/sex: 20-24 Female 2018 1,800
PP_PREV Age/sex: 20-24 Male 2018 1,800
PP_PREV Age/sex: 25-49 Female 2018 1,783
PP_PREV Age/sex: 25-49 Male 2018 2,200
PP_PREV Age/sex: 50+ Female 2018 200
PP_PREV Age/sex: 50+ Male 2018 200
PP_PREV Number of the target population who completed a standardized HIV prevention intervention including the minimum components during the reporting period 2018 14,583
PP_PREV Sum of Age/Sex disaggregates 2018 14,583
TX_CURR Aggregated Age/Sex: <15 Female 2018 13
TX_CURR Aggregated Age/Sex: <15 Male 2018 12
TX_CURR Aggregated Age/Sex: 15+ Female 2018 89
TX_CURR Aggregated Age/Sex: 15+ Male 2018 35
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2018 149
TX_CURR Sum of Aggregated Age/Sex <15 2018 25
TX_CURR Sum of Aggregated Age/Sex 15+ 2018 124
TX_CURR Sum of Aggregated Age/Sex disaggregates 2018 149
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2018 8
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2018 8
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2018 73
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2018 31
TX_NEW Breastfeeding status 2018 10
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2018 120
TX_NEW Pregnancy status 2018 5
TX_NEW Sum of Aggregated Age/Sex disaggregates 2018 120
VMMC_CIRC By Age: 10-14 2018 800
VMMC_CIRC By Age: 15-19 2018 874
VMMC_CIRC By Age: 20-24 2018 437
VMMC_CIRC By Age: 25-29 2018 145
VMMC_CIRC By Age: 30-49 2018 90
VMMC_CIRC By Age: 50+ 2018 80
VMMC_CIRC By circumcision technique: Surgical VMMC 2018 2,426
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2018 2,426
VMMC_CIRC Sum of age disaggregates (FY15-Current) 2018 2,426
VMMC_CIRC Sum of age disaggregates (Prior to FY15) 2018 2,191